Identification of a peptide that protects the human acetylcholine receptor against antigenic modulation

Journal of Immunological Methods

Volumn 251, Issue 1-2, 2001, Pages 177-186

  Luo, Guang X ^a   Victor, Kimberly ^a   Chong, Korey ^a   McNeeley, Patricia ^a   Ramirez, David ^a   Preclaro, Joddi ^a   Linnik, Matthew D ^a   Campbell, Mary Ann ^a  

^a La Jolla Pharmaceutical Company   (United States)

Author keywords

Antigens peptides epitope; Autoimmunity; Myasthenia gravis; Phage display

Indexed keywords

ALANINE; CHOLINERGIC RECEPTOR; GLUTAMIC ACID; MONOCLONAL ANTIBODY; PEPTIDE LIBRARY; PROTEIN; PROTEIN MG15; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIBODY SCREENING; ANTIGEN BINDING; ANTIGENIC MODULATION; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; IMMUNOGENICITY; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RAT; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; HUMANS; KINETICS; PEPTIDE LIBRARY; PEPTIDES; RATS; RECEPTORS, CHOLINERGIC; SURFACE PLASMON RESONANCE;

EID: 0035342550     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(01)00296-4     Document Type: Article

References (40)

1. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis
2. Monoclonal antibodies to the main immunogenic region of the nicotinic acetylcholine receptor bind to residues 61-76 of the alpha subunit
3. Mapping the main immunogenic region and toxin binding site of the nicotininc acetylcholine receptor
4. Acetylcholine receptor: An allosteric protein
5. Peptides on phage: A vast library of peptides for identifying ligands
6. Identification of peptides, selected by phage display technology, that inhibit von Willebrand factor binding to collagen
7. Antibody-mediated mechanisms of ACh receptor loss in myasthenia gravis: Clinical relevance
8. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis
9. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation
10. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site
11. Anti-acetylcholine receptor Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies
12. Epitopes on human acetylcholine receptor defined by monoclonal antibodies and myasthenia gravis sera
13. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
14. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1
15. Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins
16. Characterisation, crystallisation and preliminary X-ray diffraction analysis of a Fab fragment of a rat monoclonal antibody with very high affinity for the human muscle acetylcholine receptor
17. Monoclonal autoantibodies to acetylcholine receptors: Evidence for a dominant idiotype and requirement of complement for pathogenicity
18. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
19. Molecular and antigenic structure of nicotinic acetylcholine receptors
20. Myasthenia gravis
21. Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG)
22. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor
23. A muscle acetylcholine receptor is expressed in the human cerebellar medulloblastoma cell line TE671
24. Isolation of erythropoietin receptor agonist peptides using evolved phage libraries
25. Long-term effects of repeated plasma exchange in myasthenia gravis
26. Autoimmune response to acetylcholine receptor
27. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis
28. Myasthenic patients' IgG causes redistribution of acetylcholine receptors: Freeze-fracture studies
29. Location of antigenic determinants on primary sequences of subunits of nicotinic acetylcholine receptor by peptide mapping
30. Fab fragments of monoclonal antibodies protect the human acetylcholine receptor against antigenic modulation caused by myasthenic sera
31. Characterization of the human cell line TE671
32. Myasthenia gravis: Passive transfer from man to mouse
33. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor
34. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies
35. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor
36. Monoclonal antibodies used to probe acetylcholine receptor structure: Localization of the main immunogenic region and detection of similarities between subunits
37. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies
38. Prevention of passively transferred experimental autoimmune myasthenia gravis by a phage library-derived cyclic peptide
39. Myasthenia gravis: Monoclonal antihuman acetylcholine receptor antibodies used to analyze antibody specificities and responses to treatment
40. Rhabdomyosarcoma cell line can be used for the isolation of soluble acetylcholine receptor and for assaying blocking and modulating autoantibodies